Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 25, Issue 1, Pages 74-80Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2012.11.004
Keywords
-
Categories
Funding
- German Research Foundation [GR1517/12-1]
- Konstanz Research School Chemical Biology
- Fritz Thyssen Foundation [AZ 10.10.2.122]
- Swiss National Science Foundation [31003A_138451]
- Swiss National Science Foundation (SNF) [31003A_138451] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Treatment of cells with interferon-gamma leads to the replacement of the constitutive catalytic proteasome subunits 131, 132, and 135 by the inducible subunits LMP2 (beta 1i), MECL-1 (beta 2i), and LMP7 (beta 5i), respectively, building the so-called immunoproteasome. The incorporation of these subunits is required for the production of numerous MHC class-I restricted T cell epitopes. Recently, new evidence for an involvement of the immunoproteasome in other facets of the immune response emerged. Investigations of autoimmune diseases in animal models and a genetic predisposition of beta 5i in human autoimmune disorders suggest a crucial function of the immunoproteasome in proinflammatory diseases. The recent elucidation of the high-resolution structure of the immunoproteasome will facilitate the design of immunoproteasome selective inhibitors for pharmacological intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available